I think I recall GNW is the 4th leading mortgage provider with 16.7% of the US market. The top 4 were lumped very closely together. The 5th margest provider was about 6%. It was very bullish!
I called and spoke to Jack today about the lack of movement in the PPS. Same ole story. They are surprised Suma launch did not move the needle. I reserved further remarks untill we see Q2 results in 2nd week of August. After that all bets are off. The natives are restless!
Not the news I wanted to hear. Thought he was a great asset to ATRS. At the ASM he was eager to answer questions. Seemed like a guy who had his heart into seeing ATRS becoming successful. Oh Well, looks like another company likes what he brings to the table. Unless it's really something else. Question now is does ATRS pay him a bonus???
On the surface the move hardly looks more attractive. Guess they paid him more or he wanted a change of scenery. Zynerba just reported a bad second Q and along way off to profitability!
I knew today was going to be a drag on the PPS. I swear just when you think ATRS can get a little spark you get something like this. I believe the stock is jinxed. Ive said it before and will again. Just disappointing to see Jim move to a company that did not report any revenues last reporting period.
The PPS has got to show some momentum after earnings. Last Q it sold off. Thus far it's been flat in a rising market. I'm afraid it's back down sub $3 if the stock can't get any upwards momentum going. No news will see the shorts take it back down.
Swalchie, will any information be out in public once 60% of the study is complete? I guess I'm asking if after 60% will the trial tell us if it's been successful thus far. I'm certain they would mandate it to continue either way. I'm sure if it were a disaster they could also call it a day. Fairly knew to AMRN but have been following it and like the risk/reward here.
Yes, I now know that. It's on page 7 of the CC transcript. Thank you for your time responding to me. I have yet to buy any shares but I did buy an Oct 2016 call option today with a $3 strike price.
I bet the next Q will be closer to 4 than 3.5. The new doses will make a difference. If Otrexup hits 50 million in Revenues than it may be turning the corner. If Suma starts grabbing market share as expected due to Teva's stocking than ATRS may start turning the corner also.
You are underestimating the potential of Suma and Mekena deal. ATRS way ahead of this company. I do not see why anyone would leave and go to this company with zero revenues. ATRS will probably report 50 M in revenue this year. ATRS has been a disaster for shareholders but they do hold promise!
I don't get it either Andre. I'll see what Jack says about it tomorrow. I'll go back to the ASM. He was anxiously engaging all shareholders questions. He seemed to be engaged and excited about what was ahead. Disappointing indeed.
I can't exactly argue with your point of view. But did you ever listen to Hobbs give an investment presentation? Finkenscher was a proven commodity. How do you know they have no handle on the business ? I believe for the first time they do have a handle on the business. Sure , who likes dilution but ATRS has quite a little pipeline for a small cap pharma company. There are partnerships with TEVA and AMAG. Two revenue generating products in the market and one possibility for the next four years thereafter.
I believe they will do close to 50 M in Revenue this year with major league potential down the road. I have more than expressed my frustration with Jack and even went to Philly last June to face management and the BOD's. But to say "they do not have a handle on their business" is just non-sense!